The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is remarkably resistant to treatments. To date, there is no drug that has been deemed as fully effective in treating the coronavirus disease...

There are four types of coronaviruses (CoVs), of which include Alpha, Beta, Gamma, and Delta coronavirus. Among them, Beta CoVs are positive-stranded, enveloped ribonucleic acid (RNA) viruses that affect...

Diverse coronavirus (CoV) strains can infect both animals and humans and bring about different diseases. CoVs are known to have caused three epidemics and pandemics in the last two decades. Therefore,...

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is the causal agent of the ongoing coronavirus disease 2019 (COVID-19), is a positive sense and highly infectious ribonucleic acid...

The global outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to the coronavirus disease 2019 (COVID-19) pandemic. As of August 25, 2021, SARS-CoV-2 has infected more...

Therapies to counteract the damage caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been few and far between, despite efforts to discover new drugs and repurpose already...

Over 2.2 million genomic sequences of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been generated since the start of the coronavirus disease 2019 (COVID-19) pandemic. As of June...

The coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has devastated the world’s healthcare and economic systems. As of August...

Due to a shortage in vaccines, the Quebec Immunization Committee (QIC) recommended that the Canadian province of Quebec defer the second dose of the coronavirus disease 2019 (COVID-19) vaccine to optimize...

Several new contributions in the health sector have been made possible by 3D printing technology in the fight against COVID-19 (coronavirus disease 2019). 3D printing or additive manufacturing (AM) has...